Altuviiio immune tolerance study for severe hemophilia A
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests a treatment called Altuviiio for children with severe hemophilia A who have developed inhibitors (antibodies that block factor replacement). The goal is to help the body become tolerant to factor therapy again, preventing bleeding episodes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child has severe hemophilia A (congenital, meaning present at birth).
- You have had a high level of inhibitor (≥5 Bethesda Units) in the past.
- The highest inhibitor level before starting this treatment was less than 1,000 Bethesda Units.
- You are under 18 years old at the start of the study.
- This is your first attempt at immune tolerance induction (ITI).
- You are currently using or planning to use emicizumab (a medication to prevent bleeding) as part of your treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a therapy called ITI (using SCT800 alone or with daratumumab) to help people with hemophilia A who have inhibitor antibodies that reduce bleeding treatments from working. It may be an option if you’re an adolescent or adult with a high inhibitor level and have not already failed this kind of immune “ITI” treatment before.
This trial tests if a new medicine, NXT007, is better than emicizumab at preventing bleeding episodes in people with hemophilia A. It may be an option for those with or without inhibitors who are willing to switch to a preventive treatment.
This trial studies a treatment approach for people with hemophilia A who develop antibodies (inhibitors) that block clotting factor FVIII. It may help those whose usual FVIII therapy is not working because of these inhibitors.
This trial tests a new medicine called NXT007 to see if it is safe and effective for people with severe or moderate hemophilia A, including those with inhibitors. It may help reduce bleeding episodes.
This trial studies how your body’s anti-factor VIII antibodies change while you are treated with emicizumab for severe hemophilia A. The goal is to better understand the immune response during treatment and whether it relates to how well therapy works.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
Hear when a new Hemophilia A With Inhibitor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.